Alpha Cognition Inc. (NASDAQ: ACOG) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT ALPHA COGNITION INC.

Alpha Cognition Inc. (NASDAQ: ACOG)
Listen to this Section


$5.89
-0.0200 ( -0.34% ) 25.3K

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Market Data


Open $5.89
Previous Close $5.91
Volume 25.3K
Market Cap $128.69M
Day Range $5.67 - $6.01
52 Week Range $4.50 - $11.54
Shares Outstanding 21.77M
Change % -0.34%
Net Change ▼ -0.0200
Insider Ownership N/A
Exchange NASDAQ
SectorBasic Materials
IndustryBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
IPO Year2021
CountryUnited States

Insider Ownership Transactions

Total Amount Purchased: 73,428.00

Date Type Amount Purchased Purchaser
2025-08-21 Buy 15000.00 Wills Robert James
2025-08-21 Buy 15000.00 Wills Robert James
2025-08-20 Buy 27778.00 MERTZ LEONARD POWELL
2024-11-15 Buy 4347.00 HAVENS JOHN PRENTISS
2024-11-15 Buy 8695.00 MERTZ LEONARD POWELL
2024-11-15 Buy 2608.00 McFadden Michael E.

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 67 Nov 13, 2025
8-k/a 8K-related 12 Oct 15, 2025
8-k 8K-related 14 Oct 14, 2025
8-k 8K-related 18 Oct 02, 2025
8-k 8K-related 12 Aug 22, 2025
4 Insider transactions 1 Aug 21, 2025
4 Insider transactions 1 Aug 20, 2025
4 Insider transactions 1 Aug 20, 2025
10-q Quarterly Reports 81 Aug 14, 2025
8-k 8K-related 12 Jun 23, 2025

Latest News


× Before browsing our site, please accept our cookies policy